Loading…
Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC
In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as pr...
Saved in:
Published in: | Clinical & experimental metastasis 2019-10, Vol.36 (5), p.433-439 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213 |
---|---|
cites | cdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213 |
container_end_page | 439 |
container_issue | 5 |
container_start_page | 433 |
container_title | Clinical & experimental metastasis |
container_volume | 36 |
creator | Gómez-Ruiz, Álvaro Jesús González-Gil, Alida Gil, José Navarro-Barrios, Álvaro Alconchel, Felipe Gil, Elena Martínez, Jerónimo Nieto, Aníbal Barceló, Francisco Cascales-Campos, Pedro Antonio |
description | In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis. |
doi_str_mv | 10.1007/s10585-019-09982-1 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2252269981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2251464952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhy0EokvhBTggS1yKhMF_kjg5rralXamiK6WcI8eegKvEWex4Ud6LB8TZLSBx4GTZ88031vwQes3oB0ap_BgYzcucUFYRWlUlJ-wJWrFcCiK5LJ6iFeUFJ7SsyjP0IoQHSmkmZfkcnQnGJZWCrdDPHXg7jQ5Uj-voO6UBX9oAKgCu4bAUZ1zr0QO-2NWXdf3uPV5f35FwfFLO4Pvt-jMeRgM9tg7v1WTBTQH_sNM3vO_T1cWBBHDBTvYA2IOO3icEjwflrXJYK6fB48mDmsDgdsZ6npLdRH3sCNF_BT8nWQz4Zru72rxEzzrVB3j1eJ6jL5-u7jc35PbuertZ3xItZD4RWaiy1ErSLG-F4sqYruWcFarLqqxVLKfATKm4BKAiK1qWt5ILQ4WuDGWciXN0cfLu_fg9QpiawQYNfa8cjDE0nOecF2n1C_r2H_RhjN6l3y0Uy4qsynmi-InSfgzBQ9fsvR2UnxtGmyXT5pRpkzJtjpk2i_rNozq2A5g_Lb9DTIA4ASGVXNrV39n_0f4CcdiuCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2251464952</pqid></control><display><type>article</type><title>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</title><source>Springer Link</source><creator>Gómez-Ruiz, Álvaro Jesús ; González-Gil, Alida ; Gil, José ; Navarro-Barrios, Álvaro ; Alconchel, Felipe ; Gil, Elena ; Martínez, Jerónimo ; Nieto, Aníbal ; Barceló, Francisco ; Cascales-Campos, Pedro Antonio</creator><creatorcontrib>Gómez-Ruiz, Álvaro Jesús ; González-Gil, Alida ; Gil, José ; Navarro-Barrios, Álvaro ; Alconchel, Felipe ; Gil, Elena ; Martínez, Jerónimo ; Nieto, Aníbal ; Barceló, Francisco ; Cascales-Campos, Pedro Antonio</creatorcontrib><description>In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.</description><identifier>ISSN: 0262-0898</identifier><identifier>EISSN: 1573-7276</identifier><identifier>DOI: 10.1007/s10585-019-09982-1</identifier><identifier>PMID: 31270731</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer Research ; Chemotherapy ; Combined Modality Therapy ; Cytoreduction Surgical Procedures - methods ; Decision making ; Female ; Follow-Up Studies ; Gastric cancer ; Hematology ; Humans ; Hyperthermia, Induced - methods ; Middle Aged ; Models, Statistical ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Nomograms ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Peritoneal Neoplasms - pathology ; Peritoneal Neoplasms - therapy ; Peritoneum ; Platinum ; Platinum - administration & dosage ; Prognosis ; Prospective Studies ; Research Paper ; Severity of Illness Index ; Surgery ; Surgical Oncology ; Survival Rate ; Taxoids - administration & dosage</subject><ispartof>Clinical & experimental metastasis, 2019-10, Vol.36 (5), p.433-439</ispartof><rights>Springer Nature B.V. 2019</rights><rights>Clinical & Experimental Metastasis is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</citedby><cites>FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</cites><orcidid>0000-0002-4056-0251</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31270731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Ruiz, Álvaro Jesús</creatorcontrib><creatorcontrib>González-Gil, Alida</creatorcontrib><creatorcontrib>Gil, José</creatorcontrib><creatorcontrib>Navarro-Barrios, Álvaro</creatorcontrib><creatorcontrib>Alconchel, Felipe</creatorcontrib><creatorcontrib>Gil, Elena</creatorcontrib><creatorcontrib>Martínez, Jerónimo</creatorcontrib><creatorcontrib>Nieto, Aníbal</creatorcontrib><creatorcontrib>Barceló, Francisco</creatorcontrib><creatorcontrib>Cascales-Campos, Pedro Antonio</creatorcontrib><title>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</title><title>Clinical & experimental metastasis</title><addtitle>Clin Exp Metastasis</addtitle><addtitle>Clin Exp Metastasis</addtitle><description>In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Cytoreduction Surgical Procedures - methods</subject><subject>Decision making</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric cancer</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hyperthermia, Induced - methods</subject><subject>Middle Aged</subject><subject>Models, Statistical</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Nomograms</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Peritoneal Neoplasms - pathology</subject><subject>Peritoneal Neoplasms - therapy</subject><subject>Peritoneum</subject><subject>Platinum</subject><subject>Platinum - administration & dosage</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Research Paper</subject><subject>Severity of Illness Index</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Taxoids - administration & dosage</subject><issn>0262-0898</issn><issn>1573-7276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc9u1DAQhy0EokvhBTggS1yKhMF_kjg5rralXamiK6WcI8eegKvEWex4Ud6LB8TZLSBx4GTZ88031vwQes3oB0ap_BgYzcucUFYRWlUlJ-wJWrFcCiK5LJ6iFeUFJ7SsyjP0IoQHSmkmZfkcnQnGJZWCrdDPHXg7jQ5Uj-voO6UBX9oAKgCu4bAUZ1zr0QO-2NWXdf3uPV5f35FwfFLO4Pvt-jMeRgM9tg7v1WTBTQH_sNM3vO_T1cWBBHDBTvYA2IOO3icEjwflrXJYK6fB48mDmsDgdsZ6npLdRH3sCNF_BT8nWQz4Zru72rxEzzrVB3j1eJ6jL5-u7jc35PbuertZ3xItZD4RWaiy1ErSLG-F4sqYruWcFarLqqxVLKfATKm4BKAiK1qWt5ILQ4WuDGWciXN0cfLu_fg9QpiawQYNfa8cjDE0nOecF2n1C_r2H_RhjN6l3y0Uy4qsynmi-InSfgzBQ9fsvR2UnxtGmyXT5pRpkzJtjpk2i_rNozq2A5g_Lb9DTIA4ASGVXNrV39n_0f4CcdiuCw</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Gómez-Ruiz, Álvaro Jesús</creator><creator>González-Gil, Alida</creator><creator>Gil, José</creator><creator>Navarro-Barrios, Álvaro</creator><creator>Alconchel, Felipe</creator><creator>Gil, Elena</creator><creator>Martínez, Jerónimo</creator><creator>Nieto, Aníbal</creator><creator>Barceló, Francisco</creator><creator>Cascales-Campos, Pedro Antonio</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4056-0251</orcidid></search><sort><creationdate>20191001</creationdate><title>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</title><author>Gómez-Ruiz, Álvaro Jesús ; González-Gil, Alida ; Gil, José ; Navarro-Barrios, Álvaro ; Alconchel, Felipe ; Gil, Elena ; Martínez, Jerónimo ; Nieto, Aníbal ; Barceló, Francisco ; Cascales-Campos, Pedro Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Cytoreduction Surgical Procedures - methods</topic><topic>Decision making</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric cancer</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hyperthermia, Induced - methods</topic><topic>Middle Aged</topic><topic>Models, Statistical</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Nomograms</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Peritoneal Neoplasms - pathology</topic><topic>Peritoneal Neoplasms - therapy</topic><topic>Peritoneum</topic><topic>Platinum</topic><topic>Platinum - administration & dosage</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Research Paper</topic><topic>Severity of Illness Index</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Taxoids - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Ruiz, Álvaro Jesús</creatorcontrib><creatorcontrib>González-Gil, Alida</creatorcontrib><creatorcontrib>Gil, José</creatorcontrib><creatorcontrib>Navarro-Barrios, Álvaro</creatorcontrib><creatorcontrib>Alconchel, Felipe</creatorcontrib><creatorcontrib>Gil, Elena</creatorcontrib><creatorcontrib>Martínez, Jerónimo</creatorcontrib><creatorcontrib>Nieto, Aníbal</creatorcontrib><creatorcontrib>Barceló, Francisco</creatorcontrib><creatorcontrib>Cascales-Campos, Pedro Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & experimental metastasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Ruiz, Álvaro Jesús</au><au>González-Gil, Alida</au><au>Gil, José</au><au>Navarro-Barrios, Álvaro</au><au>Alconchel, Felipe</au><au>Gil, Elena</au><au>Martínez, Jerónimo</au><au>Nieto, Aníbal</au><au>Barceló, Francisco</au><au>Cascales-Campos, Pedro Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC</atitle><jtitle>Clinical & experimental metastasis</jtitle><stitle>Clin Exp Metastasis</stitle><addtitle>Clin Exp Metastasis</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>36</volume><issue>5</issue><spage>433</spage><epage>439</epage><pages>433-439</pages><issn>0262-0898</issn><eissn>1573-7276</eissn><abstract>In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>31270731</pmid><doi>10.1007/s10585-019-09982-1</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4056-0251</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0262-0898 |
ispartof | Clinical & experimental metastasis, 2019-10, Vol.36 (5), p.433-439 |
issn | 0262-0898 1573-7276 |
language | eng |
recordid | cdi_proquest_miscellaneous_2252269981 |
source | Springer Link |
subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Cancer Research Chemotherapy Combined Modality Therapy Cytoreduction Surgical Procedures - methods Decision making Female Follow-Up Studies Gastric cancer Hematology Humans Hyperthermia, Induced - methods Middle Aged Models, Statistical Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Nomograms Oncology Ovarian cancer Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Peritoneal Neoplasms - pathology Peritoneal Neoplasms - therapy Peritoneum Platinum Platinum - administration & dosage Prognosis Prospective Studies Research Paper Severity of Illness Index Surgery Surgical Oncology Survival Rate Taxoids - administration & dosage |
title | Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A25%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peritoneal%20Surface%20Disease%20Severity%20Score%20(PSDSS),%20AGO-score%20and%20TIAN%20model%20in%20patients%20with%20platinum-sensitive%20recurrent%20ovarian%20cancer%20treated%20by%20cytoreductive%20surgery%20plus%20HIPEC&rft.jtitle=Clinical%20&%20experimental%20metastasis&rft.au=G%C3%B3mez-Ruiz,%20%C3%81lvaro%20Jes%C3%BAs&rft.date=2019-10-01&rft.volume=36&rft.issue=5&rft.spage=433&rft.epage=439&rft.pages=433-439&rft.issn=0262-0898&rft.eissn=1573-7276&rft_id=info:doi/10.1007/s10585-019-09982-1&rft_dat=%3Cproquest_cross%3E2251464952%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-76a88ca7045b3a2addfb2216af494ba150e1d8a27ee0346b15b723d03c9d01213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2251464952&rft_id=info:pmid/31270731&rfr_iscdi=true |